IPC Healthcare (IPCM) Inactive 10-Q25 Apr 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2014	Apr. 18, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'IPCM	'
Entity Registrant Name	'IPC The Hospitalist Company, Inc.	'
Entity Central Index Key	'0001410471	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	17,131,994

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$23,274	$25,010
Accounts receivable, net	117,649	103,585
Insurance receivable for malpractice claims - current portion	12,076	11,653
Prepaid expenses and other current assets	15,076	19,378
Total current assets	168,075	159,626
Property and equipment, net	6,238	6,343
Goodwill	361,325	357,387
Other intangible assets, net	5,565	5,857
Insurance receivable for malpractice claims - less current portion	21,341	20,599
Total assets	562,544	549,812
Current liabilities:	'	'
Accounts payable and accrued liabilities	9,746	5,486
Accrued compensation	38,409	35,639
Payable for practice acquisitions, current portion	28,574	32,430
Medical malpractice and self-insurance reserves, current portion	12,690	12,211
Deferred tax liabilities, current portion	969	969
Total current liabilities	90,388	86,735
Long-term debt	85,000	90,000
Medical malpractice and self-insurance reserves, less current portion	45,353	44,044
Payable for practice acquisitions, less current portion	6,272	8,289
Deferred tax liabilities, less current portion	5,762	5,762
Total liabilities	232,775	234,830
Stockholders' equity:	'	'
Preferred stock, $0.001 par value, 15,000,000 shares authorized, none issued	0	0
Common stock, $0.001 par value, 50,000,000 shares authorized, 17,125,914 and 17,015,580 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively	17	17
Additional paid-in capital	172,439	167,926
Retained earnings	157,313	147,039
Total stockholders' equity	329,769	314,982
Total liabilities and stockholders' equity	$562,544	$549,812

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	15,000,000	15,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	17,125,914	17,015,580
Common stock, shares outstanding	17,125,914	17,015,580

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]	'	'
Net revenue	$172,726	$153,091
Operating expenses:	'	'
Cost of services-physician practice salaries, benefits and other	127,273	112,068
General and administrative	27,607	23,823
Net change in fair value of contingent consideration	-383	-1,093
Depreciation and amortization	1,265	1,154
Total operating expenses	155,762	135,952
Income from operations	16,964	17,139
Investment income	1	2
Interest expense	-314	-115
Income before income taxes	16,651	17,026
Income tax provision	6,377	6,521
Net income	$10,274	$10,505
Net income per share:	'	'
Basic	$0.60	$0.63
Diluted	$0.58	$0.61

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Operating activities	'	'
Net income	$10,274	$10,505
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation and amortization	1,265	1,154
Stock-based compensation expense	1,965	1,735
Changes in assets and liabilities:	'	'
Accounts receivable	-14,064	-12,136
Prepaid expenses and other current assets	4,270	4,248
Accounts payable and accrued liabilities	4,260	3,839
Accrued compensation	2,770	4,796
Medical malpractice and self-insurance reserves, net	623	899
Accrued contingent consideration	-1,189	-1,093
Net cash provided by operating activities	10,174	13,947
Investing activities	'	'
Acquisitions of physician practices	-8,740	-9,691
Purchase of property and equipment	-750	-1,113
Net cash used in investing activities	-9,490	-10,804
Financing activities	'	'
Repayments of long-term debt	-5,000	0
Net proceeds from issuance of common stock	2,160	1,333
Excess tax benefits from stock-based compensation	420	317
Net cash (used in) provided by financing activities	-2,420	1,650
Net (decrease) increase in cash and cash equivalents	-1,736	4,793
Cash and cash equivalents, beginning of period	25,010	16,214
Cash and cash equivalents, end of period	23,274	21,007
Supplemental disclosure of cash flow information Cash paid for:	'	'
Interest	102	75
Income taxes	$635	$490

Basis_of_Presentation_and_Sign

Basis of Presentation and Significant Accounting Policies	3 Months Ended
Basis of Presentation and Significant Accounting Policies	Mar. 31, 2014
Accounting Policies [Abstract]	'
Basis of Presentation and Significant Accounting Policies	'
	Note 1. Basis of Presentation and Significant Accounting Policies
	Basis of Presentation
	IPC The Hospitalist Company, Inc. and its wholly-owned subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time hospitalist practices. We prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) on the same basis as our audited annual financial statements. The consolidated financial statements include all accounts of IPC The Hospitalist Company, Inc. and its wholly owned subsidiaries and consolidated professional medical corporations (Professional Medical Corporations) managed under long-term management agreements.
	Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have control over the operations of these VIE’s, provide full financial and management support to them, and take all residual benefits and bear all residual losses from their operations. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation.
	In our opinion, these consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial information set forth therein. Certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to GAAP and SEC rules and regulations, which are applicable to interim financial statements. As a result, the following disclosures should be read in conjunction with our audited consolidated financial statements and notes thereto as of December 31, 2013 included in our Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on February 26, 2014.
	Revenue
	Net revenue consists of fees for medical services provided by our affiliated hospitalists under fee-for-service, case rate and other professional fee arrangements with various payors including Medicare, Medicaid, managed care organizations, insurance companies and hospitals. Net revenue is reported in the period in which services are provided at amounts expected to be collected, which excludes contractual discounts and an estimate of uncollectible accounts.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. Significant estimates include the estimated net realizable value of accounts receivable, medical malpractice insurance receivable and payable for known claims, liabilities for claims incurred but not reported (IBNR) related to medical malpractice, fair value of contingent consideration related to business combinations and the analysis of goodwill for impairment. The process of estimating these assets and liabilities involves judgment decisions, which are subject to an inherent degree of uncertainty. Actual results could differ from those estimates. The results of operations for the current interim period are not necessarily indicative of the results for the entire year ending December 31, 2014.
	Fair Value of Financial Instruments
	Our consolidated balance sheets as of March 31, 2014 and December 31, 2013 included the following financial instruments: cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, payable for practice acquisitions and long-term debt. We consider the carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amount of our long-term debt borrowed from our line of credit approximated its fair value at March 31, 2014 and December 31, 2013. Pursuant to GAAP, we determine the fair value of our long-term borrowing using observable inputs, which is defined as Level 2 input under GAAP on fair value measures.

	Our payable for practice acquisitions consisted of accrued contingent consideration for practice acquisitions. The accrued contingent consideration is carried at fair value largely determined using the income approach with unobservable inputs defined as Level 3 inputs under GAAP. See Note 3 for more information.
	Goodwill
	The changes in the carrying amount of goodwill for the three months ended March 31, 2014 are as follows (in thousands):


	Goodwill - beginning balance at January 1, 2014	$	357,387
	Goodwill acquired during 2014		5,799
	Adjustment for prior year transactions		(1,861	)

	Goodwill - ending balance at March 31, 2014	$	361,325

	The valuation studies related to the practice acquisitions that occurred in the fourth quarter of 2013 were completed in early 2014, and as a result, the value of contingent consideration liability related to these acquisitions as of the acquisition dates was reduced by $1,861,000, along with a corresponding reduction in our goodwill.
	Medical Malpractice Liability Insurance
	We record our medical malpractice reserves, on an undiscounted basis, for claims incurred and reported and claims incurred but not reported (IBNR) during the policy period, based on actuarial loss projections using historical loss patterns. For claims incurred and reported, an insurance receivable from our carrier has been recorded pursuant to GAAP. Total accrued medical malpractice reserves and related insurance receivables were as follows (in thousands):


		March 31, 2014									December 31, 2013
		Assets			Liabilities						Assets		Liabilities
		Insurance			Claims		IBNR		Total		Insurance		Claims		IBNR		Total
		Receivable			Reserve		Reserve		Liabilities		Receivable		Reserve		Reserve		Liabilities
	Current Portion	$	12,076		$	12,076		614		12,690	$	11,653	$	11,653		558		12,211
	Long-term Portion		21,341			21,341		24,012		45,353		20,599		20,599		23,445		44,044

	Total	$	33,417		$	33,417		24,626		58,043	$	32,252	$	32,252		24,003		56,255

Business_Acquisitions

Business Acquisitions	3 Months Ended
Business Acquisitions	Mar. 31, 2014
Business Combinations [Abstract]	'
Business Acquisitions	'
	Note 2. Business Acquisitions
	For practice acquisitions, we recognize all of the assets acquired, liabilities assumed and any contingent consideration at the acquisition-date fair value and expense all transaction related costs.
	During the three months ended March 31, 2014, we completed the acquisition of three hospitalist physician practices. In connection with these acquisitions, we recorded goodwill and other identifiable intangible assets consisting of physician and hospital agreements.
	Goodwill represents the potential business synergy from the combined operations of our existing and acquired practices through an expanded national network of providers, improved managed care contracting, improved collections, identification of growth initiatives and cost savings based upon the significant infrastructure we have developed. Amounts recorded as goodwill and identifiable intangible assets with indefinite lives are not amortizable for GAAP financial reporting purpose but are amortized for tax purposes over 15 years.

	In addition to the initial consideration paid at the close of each transaction, the asset purchase agreements for the three acquisitions completed during the three months ended March 31, 2014 provide for contingent consideration to be paid, which is generally based upon the achievement of certain operating results of the acquired practices as of certain measurement dates. These additional payments are not contingent upon the future employment of the sellers. The contingent consideration for the three acquisitions completed during the three months ended March 31, 2014 was recorded on a provisional basis pending completion of the valuation studies as of the acquisition dates.
	We estimate the fair value of contingent consideration to be paid based on discounted projected earnings of the acquired practices as of certain measurement dates. The discount rate that we use consists of a risk-free U.S. Treasury bond yield plus a Company specific credit spread which we believe is acceptable by willing market participants.
	The following table summarizes the total amounts recorded during the three months ended March 31, 2014, related to the acquisition of hospitalist practices (in thousands):


	Acquired assets – paid and accrued:
	Goodwill - 2014 transactions	$	5,799
	Other intangible assets		118

	Total acquired assets - 2014		5,917
	Goodwill - adjustment for prior year transactions		(1,861	)

			4,056

	Cash paid for acquisitions:
	2014 transactions		(3,025	)
	Contingent consideration		(5,715	)

	Total cash paid for acquisitions		(8,740	)

	Change in fair value of contingent consideration:
	Net change in fair value of contingent consideration - recognized		(383	)
	Net change in fair value of contingent consideration - paid		(806	)

	Net change in fair value of contingent consideration		(1,189	)

	Net change in payable for practice acquisitions		(5,873	)
	Payable for practice acquisitions, beginning of period		40,719

	Payable for practice acquisitions, end of period	$	34,846

Fair_Value_Measurement

Fair Value Measurement

3 Months Ended

Mar. 31, 2014

Fair Value Disclosures [Abstract]

Fair Value Measurement

Note 3. Fair Value Measurement

Some of our liabilities are measured and recorded at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The established fair value hierarchy distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (Levels 1 and 2) and the reporting entity’s own assumptions about market participant assumptions (Level 3). This hierarchy is used to measure fair value as follows:

•

Level 1 inputs utilize quoted prices in active markets for identical assets or liabilities.

•

Level 2 inputs include quoted prices for similar assets and liabilities in active markets; quoted prices in markets that are not active; and other inputs that are observable or can be corroborated by observable market data for the asset or liability.

•

Level 3 inputs are unobservable inputs for the asset or liability that are supported by little or no market activity.

The following table presents our liabilities measured at fair value on a recurring basis as of March 31, 2014 (in thousands):

Quoted Price In

Significant Other

Significant

Active Markets for

Observable

Unobservable

Identical Instruments

Inputs

(Level 1)

(Level 2)

(Level 3)

Total Balance

Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)

34,846

The following table presents a rollforward of our liabilities measured at fair value on a recurring basis using significant unobservable inputs (level 3) for the three months ended March 31, 2014 (in thousands):

Three Months

Ended

March 31, 2014

Accrued contingent consideration for practice acquisitions

Beginning balance

40,719

Addition through acquisition transactions

2,892

Adjustment for prior year transactions

(1,861

)

Change in fair value recognized

(383

)

Change in fair value paid

(806

)

Payments

(5,715

)

Ending balance

34,846

The fair value of our accrued contingent consideration is determined using widely accepted valuation techniques, which include the income approach for estimating future consideration to be paid based on projected earnings of our acquired practices as of specified measurement dates. The income approach involves the use of a probability-weighted discounted cash flow model based on significant inputs not observable in the market. The significant inputs include discount rates of 2.04% to 2.35%, 100% probability of achieving the estimated projected earnings, and 25% to 90% probability of the acquisition of certain other hospitalist practices.

Because our accrued contingent consideration is generally based on a certain multiple of earnings of the acquired practices during a specified measurement period, a moderate change in such projected earnings may result in a material change to the fair value of such contingent consideration liability with a corresponding adjustment to income from operations. We reassess our projected earnings and the related fair value of our accrued contingent consideration for practice acquisitions on a quarterly basis.

Debt

Debt	3 Months Ended
Debt	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Debt	'
	Note 4. Debt
	Our secured revolving credit agreement (Credit Facility) provides a revolving line of credit of $125.0 million and contains an “accordion” feature that allows an increase of up to $25.0 million to the Credit Facility with lender approval. The Credit Facility has a maturity date of August 4, 2016 and is available for working capital, practice acquisitions, capital expenditures and general business expenses. As of March 31, 2014, we had borrowings of $85.0 million and letters of credit of $0.3 million outstanding, and $39.7 million available under the Credit Facility.
	The revolving line of credit is limited by a formula based on a certain multiple times the trailing twelve months of earnings before interest, taxes, depreciation, amortization and certain non-cash items. Interest rate options for each borrowing under the Credit Facility, to be selected by us at the time of each borrowing, include either LIBOR plus 0.75% to 1.75%, or the lender’s prime rate plus 0% to 0.75%, both based on a leverage ratio. We pay an unused commitment fee equal to 0.25% per annum on the difference between the revolving line capacity and the average balance outstanding during the year. Outstanding amounts advanced to us under the revolving line of credit are repayable on or before the maturity date. The interest rate for our borrowings under the Credit Facility at March 31, 2014 was 1.4375% per annum.

	The Credit Facility is guaranteed by our subsidiaries and affiliated Professional Medical Corporations and limited liability companies, and is secured by substantially all of our and our guarantors’ tangible and intangible assets. The Credit Facility includes various customary financial covenants and restrictions, as well as customary remedies for our lenders following an event of default. As of March 31, 2014, we were in compliance with such financial covenants and restrictions.

Income_Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Note 5. Income Taxes
	Following are the income tax provisions and effective tax rates for the three months ended March 31, 2014 and 2013 (dollars in thousands):


		Three Months Ended March 31,
		2014			2013
	Income tax provision	$	6,377		$	6,521

	Effective tax rate		38.3	%		38.3	%

	The effective tax rates differ from the statutory U.S. federal income tax rate of 35.0% due primarily to state income taxes.
	Our accounting policy is to include interest and penalties related to income tax liabilities in income tax expense. As of March 31, 2014, we did not have any estimated interest and penalties related to uncertain tax positions.
	The tax years 2009 to 2012 remain open to examination by the major taxing jurisdictions to which we are subject. The statute of limitations for tax years 1999 to 2008 has expired, except that the tax year 1999 is subject to adjustment of net operating losses by the Internal Revenue Service. We are subject to taxation in the United States and various state jurisdictions. The Company is currently subject to one state tax examination for the tax year of 2009. The outcome of the examination cannot be predicted with certainty; however, we believe that the ultimate resolution will not have a material effect on our consolidated financial position, results of operations, or cash flows.
	We make our best estimate of the tax rate expected to be applicable for the full fiscal year. The rate so determined is used to compute our income tax expense for an interim period.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
Stock-Based Compensation	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	Note 6. Stock-Based Compensation
	At March 31, 2014, we had a stock-based employee compensation program, for which we had reserved a total of 4,943,170 common shares for issuance. Under our 2012 Equity Participation Plan (Equity Plan), which was approved by our stockholders on June 7, 2012, a total of 1,422,130 shares of our common stock were available for issuance and no new awards will be issued under any previous equity participation plans. As of March 31, 2014, there were 894,596 shares of our common stock available for future grants under our Equity Plan, which included the canceled and forfeited shares issued under previous equity participation plans.
	All option awards granted during the three months ended March 31, 2014 were issued with exercise prices equal to the closing price of our common stock on the NASDAQ Global Select Market on the dates of the grant. The options under the Equity Plan generally vest over a four-year period from date of grant, and options terminate on the 10th anniversary of the agreement date for all grants issued before January 1, 2013 and on the 7th anniversary of the agreement date for all grants issued after December 31, 2012. Restricted stock awards generally vest over a four-year period from date of the award. Performance stock awards generally vest over two to three years from date of the award based on the expected level of achievement of certain operational goals that will be obtained and adjusted as appropriate to reflect actual shares issued.
	Stock-based compensation expense is recognized over the period when the options, restricted stock awards, performance stock awards and our employee stock purchase plan shares vest, which is included in total general and administrative expenses as follows (in thousands):


		Three months ended March 31,
		2014				2013
	Total stock-based compensation expense	$	1,965			$	1,735
	Tax benefit from stock-based compensation expense		(753	)			(665	)

	Total stock-based compensation expense, net of tax	$	1,212			$	1,070

	As of March 31, 2014, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under our Equity Plan and previous equity participation plans and the weighted-average period of years expected to recognize those costs are as follows (dollars in thousands):


		Total Unrecognized				Weighted -average
		Compensation Cost				Remaining Recognition
						Period
						(Years)
	Stock option	$	3,790				1.77

	Restricted/Performance stock	$	9,757				2.46

	The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions:


		Three months ended March 31,
		2014				2013
	Risk-free interest rate		1.03	%			0.66	%
	Expected volatility		37.05	%			40.09	%
	Expected option life (in years)		4.39				4.42
	Expected dividend yield		0	%			0	%
	The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero coupon issues. The expected volatility is largely based on the volatility of our stock price. The expected option life of each award granted was calculated using the “simplified method” in accordance with GAAP.
	The grant date fair value of each restricted stock award or performance stock award is based on the closing stock price on the grant date of the award as reported by NASDAQ Global Select Market.

	The following table summarizes the stock option activities in our Equity Plan during the three months ended March 31, 2014.


		Shares				Weighted-				Weighted-			Aggregate		Weighted-
						Average				Average			Intrinsic Value		Average Fair
						Exercise Price				Remaining					Value
										Contractual
										Term
										(Years)			(in 000s)
	Options outstanding as of December 31, 2013		1,380,425			$	30.12								$	12.56
	Changes during period:
	Granted		39,138				55.12									17.49
	Exercised		(34,129	)			29.81									12.88
	Cancelled		(9,638	)			43.34									18.11

	Options outstanding as of March 31, 2014		1,375,796			$	30.74				5.68		$	25,475	$	12.66

	Options exercisable as of March 31, 2014		1,139,101			$	28.24				5.35		$	23,781	$	11.8

	The following table summarizes the restricted stock award and performance stock award activities in our Equity Plan during the three months ended March 31, 2014.


		Shares				Weighted-				Aggregate			Weighted-
						Average				Intrinsic			Average
						Remaining				Value			Fair Value
						Contractual
						Term
					(Years)				(in 000s)
Restricted/performance stock awards outstanding as of December 31, 2013		212,413										$	40.29
Changes during period:
Granted		111,360											52.5
Released		(53,080	)										38.69
Forfeited		(5,402	)										40.97

Restricted/performance stock awards outstanding as of March 31, 2014		265,291				1.88			$	12,184		$	45.72

Earnings_Per_Share

Earnings Per Share	3 Months Ended
Earnings Per Share	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Note 7. Earnings Per Share
	Basic net income per share is calculated by dividing net income for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing net income for the period by the weighted average number of shares outstanding during the period plus the dilutive effect of our outstanding stock awards and shares issuable under our employee stock purchase plan using the treasury stock method.

	The calculations of basic and diluted net income per share for the three months ended March 31, 2014 and 2013 are as follows (dollars in thousands, except for per share data):


		Three Months Ended
		March 31,
		2014		2013
	Basic:
	Net income attributable to common stockholders	$	10,274	$	10,505

	Weighted average number of common shares outstanding		17,054,598		16,703,369

	Basic net income per share attributable to common stockholders	$	0.6	$	0.63

	Diluted:
	Net income attributable to common stockholders	$	10,274	$	10,505

	Weighted average number of common shares outstanding		17,054,598		16,703,369
	Weighted average number of dilutive common share equivalents from options to purchase common stock		512,985		422,571

	Common shares and common share equivalents		17,567,583		17,125,940

	Diluted net income per share	$	0.58	$	0.61

	Outstanding stock options that have an above-market exercise price or that are anti-dilutive under the treasury stock method, are excluded from our diluted computation. As of March 31, 2014, the total number of excluded stock options was 41,254.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Note 8. Commitments and Contingencies
	Legal
	In the ordinary course of our business, we become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services provided by our affiliated hospitalists. We may also become subject to other lawsuits, which could involve significant claims and/or significant defense costs.
	We believe, based upon our review of pending actions and proceedings, that the outcome of such legal actions and proceedings will not have a material adverse effect on our business, financial condition, results of operations, or cash flows. The outcome of such actions and proceedings, however, cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, financial condition, results of operations, or cash flows in a future period.
	Government Inquiry
	On June 7, 2010, we received a civil investigative demand (CID) issued by the Department of Justice (DOJ), U.S. Attorney’s Office for the Northern District of Illinois. The CID requested information concerning claims that we have submitted to Medicare and Medicaid. The CID covered the period from January 1, 2003, through June 4, 2010, and requested production of a range of documents relating to our Medicare and Medicaid participation, physician arrangements, operations, billings and compliance programs. We believe we have a strong compliance focus, and that we operate with appropriate billing policies, procedures, provider training, and compliance programs and controls. We produced responsive documents and have been in contact with representatives of the DOJ who informed us that the inquiry related to a qui tam whistleblower action filed under court seal in the U.S. District Court for the Northern District of Illinois (Chicago). We also were informed that several state attorneys general were examining our Medicaid claims in coordination with the DOJ.
	On December 6, 2013, the U.S. District Court partially lifted the seal on the civil False Claims Act case related to this investigation. The unsealed portions of the Court docket include the whistleblower’s Complaint, which contains allegations of improper billing to Medicare and Medicaid, a Notice of Election to Intervene filed by the federal government and a Notice of Election to Decline Intervention filed by the State of Illinois and 12 other states that participated in the investigation. We have cooperated with the government’s investigation and continue to have discussions with the federal government regarding its investigation and the related case.

	It is not possible to predict when this matter may be resolved or what impact, if any, the outcome of this matter might have on our consolidated financial position, results of operations, or cash flows.

Basis_of_Presentation_and_Sign1

Basis of Presentation and Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Basis of Presentation

IPC The Hospitalist Company, Inc. and its wholly-owned subsidiaries (the “Company,” “IPC,” “we,” “us,” and “our”) is a national physician group practice company that operates and manages full-time hospitalist practices. We prepared the accompanying unaudited consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) on the same basis as our audited annual financial statements. The consolidated financial statements include all accounts of IPC The Hospitalist Company, Inc. and its wholly owned subsidiaries and consolidated professional medical corporations (Professional Medical Corporations) managed under long-term management agreements.

Through the management agreements and our relationship with the stockholders of the Professional Medical Corporations, we have exclusive authority over all non-medical decision making related to the ongoing business operations of the Professional Medical Corporations. Further, our rights under the management agreements are unilaterally salable or transferable. Based on the provisions of the agreements, we have determined that the Professional Medical Corporations are variable interest entities (VIE’s), and that we are the primary beneficiary because we have control over the operations of these VIE’s, provide full financial and management support to them, and take all residual benefits and bear all residual losses from their operations. Consequently, we consolidate the revenue and expenses of the Professional Medical Corporations from the date of execution of the agreements. All intercompany balances and transactions have been eliminated in consolidation.

In our opinion, these consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the financial information set forth therein. Certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been condensed or omitted pursuant to GAAP and SEC rules and regulations, which are applicable to interim financial statements. As a result, the following disclosures should be read in conjunction with our audited consolidated financial statements and notes thereto as of December 31, 2013 included in our Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on February 26, 2014.

Revenue

Net revenue consists of fees for medical services provided by our affiliated hospitalists under fee-for-service, case rate and other professional fee arrangements with various payors including Medicare, Medicaid, managed care organizations, insurance companies and hospitals. Net revenue is reported in the period in which services are provided at amounts expected to be collected, which excludes contractual discounts and an estimate of uncollectible accounts.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions of the fair value of certain reported amounts of assets, liabilities, revenues and expenses at the date and for the periods that the financial statements are prepared. Significant estimates include the estimated net realizable value of accounts receivable, medical malpractice insurance receivable and payable for known claims, liabilities for claims incurred but not reported (IBNR) related to medical malpractice, fair value of contingent consideration related to business combinations and the analysis of goodwill for impairment. The process of estimating these assets and liabilities involves judgment decisions, which are subject to an inherent degree of uncertainty. Actual results could differ from those estimates. The results of operations for the current interim period are not necessarily indicative of the results for the entire year ending December 31, 2014.

Fair Value of Financial Instruments

Our consolidated balance sheets as of March 31, 2014 and December 31, 2013 included the following financial instruments: cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, payable for practice acquisitions and long-term debt. We consider the carrying amounts of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities to approximate their fair value because of the relatively short period of time between the origination of these instruments and their expected realization. The carrying amount of our long-term debt borrowed from our line of credit approximated its fair value at March 31, 2014 and December 31, 2013. Pursuant to GAAP, we determine the fair value of our long-term borrowing using observable inputs, which is defined as Level 2 input under GAAP on fair value measures.

Our payable for practice acquisitions consisted of accrued contingent consideration for practice acquisitions. The accrued contingent consideration is carried at fair value largely determined using the income approach with unobservable inputs defined as Level 3 inputs under GAAP. See Note 3 for more information.

Goodwill

The changes in the carrying amount of goodwill for the three months ended March 31, 2014 are as follows (in thousands):

Goodwill - beginning balance at January 1, 2014

357,387

Goodwill acquired during 2014

5,799

Adjustment for prior year transactions

(1,861

)

Goodwill - ending balance at March 31, 2014

361,325

The valuation studies related to the practice acquisitions that occurred in the fourth quarter of 2013 were completed in early 2014, and as a result, the value of contingent consideration liability related to these acquisitions as of the acquisition dates was reduced by $1,861,000, along with a corresponding reduction in our goodwill.

Medical Malpractice Liability Insurance

We record our medical malpractice reserves, on an undiscounted basis, for claims incurred and reported and claims incurred but not reported (IBNR) during the policy period, based on actuarial loss projections using historical loss patterns. For claims incurred and reported, an insurance receivable from our carrier has been recorded pursuant to GAAP. Total accrued medical malpractice reserves and related insurance receivables were as follows (in thousands):

March 31, 2014

December 31, 2013

Assets

Liabilities

Assets

Liabilities

Insurance

Claims

IBNR

Total

Insurance

Claims

IBNR

Total

Receivable

Reserve

Liabilities

Receivable

Reserve

Liabilities

Current Portion

12,076

614

12,690

11,653

558

12,211

Long-term Portion

21,341

24,012

45,353

20,599

23,445

44,044

Total

33,417

24,626

58,043

32,252

24,003

56,255

Basis_of_Presentation_and_Sign2

Basis of Presentation and Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Schedule of Changes in Carrying Amount of Goodwill	'
	The changes in the carrying amount of goodwill for the three months ended March 31, 2014 are as follows (in thousands):


	Goodwill - beginning balance at January 1, 2014	$	357,387
	Goodwill acquired during 2014		5,799
	Adjustment for prior year transactions		(1,861	)

	Goodwill - ending balance at March 31, 2014	$	361,325

Schedule of Total Accrued Medical Malpractice Reserves and Related Insurance Receivables	'
	Total accrued medical malpractice reserves and related insurance receivables were as follows (in thousands):


		March 31, 2014									December 31, 2013
		Assets			Liabilities						Assets		Liabilities
		Insurance			Claims		IBNR		Total		Insurance		Claims		IBNR		Total
		Receivable			Reserve		Reserve		Liabilities		Receivable		Reserve		Reserve		Liabilities
	Current Portion	$	12,076		$	12,076		614		12,690	$	11,653	$	11,653		558		12,211
	Long-term Portion		21,341			21,341		24,012		45,353		20,599		20,599		23,445		44,044

	Total	$	33,417		$	33,417		24,626		58,043	$	32,252	$	32,252		24,003		56,255

Business_Acquisitions_Tables

Business Acquisitions (Tables)	3 Months Ended
Business Acquisitions (Tables)	Mar. 31, 2014
Business Combinations [Abstract]	'
Schedule of Acquisition of Hospitalist Practices	'
	The following table summarizes the total amounts recorded during the three months ended March 31, 2014, related to the acquisition of hospitalist practices (in thousands):


	Acquired assets – paid and accrued:
	Goodwill - 2014 transactions	$	5,799
	Other intangible assets		118

	Total acquired assets - 2014		5,917
	Goodwill - adjustment for prior year transactions		(1,861	)

			4,056

	Cash paid for acquisitions:
	2014 transactions		(3,025	)
	Contingent consideration		(5,715	)

	Total cash paid for acquisitions		(8,740	)

	Change in fair value of contingent consideration:
	Net change in fair value of contingent consideration - recognized		(383	)
	Net change in fair value of contingent consideration - paid		(806	)

	Net change in fair value of contingent consideration		(1,189	)

	Net change in payable for practice acquisitions		(5,873	)
	Payable for practice acquisitions, beginning of period		40,719

	Payable for practice acquisitions, end of period	$	34,846

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)

3 Months Ended

Mar. 31, 2014

Fair Value Disclosures [Abstract]

Liabilities Measured at Fair Value on Recurring Basis

The following table presents our liabilities measured at fair value on a recurring basis as of March 31, 2014 (in thousands):

Quoted Price In

Significant Other

Significant

Active Markets for

Observable

Unobservable

Identical Instruments

Inputs

(Level 1)

(Level 2)

(Level 3)

Total Balance

Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)

34,846

Rollforward for Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs

Three Months

Ended

March 31, 2014

Accrued contingent consideration for practice acquisitions

Beginning balance

40,719

Addition through acquisition transactions

2,892

Adjustment for prior year transactions

(1,861

)

Change in fair value recognized

(383

)

Change in fair value paid

(806

)

Payments

(5,715

)

Ending balance

34,846

Income_Taxes_Tables

Income Taxes (Tables)	3 Months Ended
Income Taxes (Tables)	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Schedule of Income Tax Provisions and Effective Tax Rates	'
	Following are the income tax provisions and effective tax rates for the three months ended March 31, 2014 and 2013 (dollars in thousands):


		Three Months Ended March 31,
		2014			2013
	Income tax provision	$	6,377		$	6,521

	Effective tax rate		38.3	%		38.3	%

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
Stock-Based Compensation (Tables)	Mar. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Schedule of Stock-Based Compensation Expense Recognized When Options, Restricted Stock Awards, Performance Stock Awards and Employee Stock Purchase Plan Shares Vested	'
	Stock-based compensation expense is recognized over the period when the options, restricted stock awards, performance stock awards and our employee stock purchase plan shares vest, which is included in total general and administrative expenses as follows (in thousands):


		Three months ended March 31,
		2014			2013
	Total stock-based compensation expense	$	1,965		$	1,735
	Tax benefit from stock-based compensation expense		(753	)		(665	)

	Total stock-based compensation expense, net of tax	$	1,212		$	1,070

Schedule of Unrecognized Compensation Costs Related to Non-Vested Stock-Based Compensation Arrangements Granted under Equity Plan and Previous Equity Participation Plans and Weighted-Average Period of Years Expected to Recognize Those Costs	'
	As of March 31, 2014, total unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under our Equity Plan and previous equity participation plans and the weighted-average period of years expected to recognize those costs are as follows (dollars in thousands):


		Total Unrecognized			Weighted -average
		Compensation Cost			Remaining Recognition
					Period
					(Years)
	Stock option	$	3,790			1.77

	Restricted/Performance stock	$	9,757			2.46

Schedule of Fair Value of Each Option Grant Estimated on Date of Grant Using Black-Scholes Option-Pricing Model	'
	The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model based on the following weighted-average assumptions:


		Three months ended March 31,
		2014			2013
	Risk-free interest rate		1.03	%		0.66	%
	Expected volatility		37.05	%		40.09	%
	Expected option life (in years)		4.39			4.42
	Expected dividend yield		0	%		0	%
Summary of Stock Option Activities in Equity Plan	'
	The following table summarizes the stock option activities in our Equity Plan during the three months ended March 31, 2014.


		Shares			Weighted-			Weighted-		Aggregate		Weighted-
					Average			Average		Intrinsic Value		Average Fair
					Exercise Price			Remaining				Value
								Contractual
								Term
								(Years)		(in 000s)
	Options outstanding as of December 31, 2013		1,380,425		$	30.12						$	12.56
	Changes during period:
	Granted		39,138			55.12							17.49
	Exercised		(34,129	)		29.81							12.88
	Cancelled		(9,638	)		43.34							18.11

	Options outstanding as of March 31, 2014		1,375,796		$	30.74			5.68	$	25,475	$	12.66

	Options exercisable as of March 31, 2014		1,139,101		$	28.24			5.35	$	23,781	$	11.8

Summary of Restricted Stock Award and Performance Stock Award Activities in Equity Plan	'
	The following table summarizes the restricted stock award and performance stock award activities in our Equity Plan during the three months ended March 31, 2014.


		Shares			Weighted-			Aggregate		Weighted-
					Average			Intrinsic		Average
					Remaining			Value		Fair Value
					Contractual
					Term
					(Years)			(in 000s)
	Restricted/performance stock awards outstanding as of December 31, 2013		212,413							$	40.29
	Changes during period:
	Granted		111,360								52.5
	Released		(53,080	)							38.69
	Forfeited		(5,402	)							40.97

	Restricted/performance stock awards outstanding as of March 31, 2014		265,291			1.88		$	12,184	$	45.72

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
Earnings Per Share (Tables)	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Schedule of Basic and Diluted Net Income Per Share	'
	The calculations of basic and diluted net income per share for the three months ended March 31, 2014 and 2013 are as follows (dollars in thousands, except for per share data):


		Three Months Ended
		March 31,
		2014		2013
	Basic:
	Net income attributable to common stockholders	$	10,274	$	10,505

	Weighted average number of common shares outstanding		17,054,598		16,703,369

	Basic net income per share attributable to common stockholders	$	0.6	$	0.63

	Diluted:
	Net income attributable to common stockholders	$	10,274	$	10,505

	Weighted average number of common shares outstanding		17,054,598		16,703,369
	Weighted average number of dilutive common share equivalents from options to purchase common stock		512,985		422,571

	Common shares and common share equivalents		17,567,583		17,125,940

	Diluted net income per share	$	0.58	$	0.61

Basis_of_Presentation_and_Sign3

Basis of Presentation and Significant Accounting Policies - Schedule of Changes in Carrying Amount of Goodwill (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Goodwill [Roll Forward]	'
Goodwill - beginning balance	$357,387
Goodwill acquired during 2014	5,799
Goodwill Adjustment for prior year transactions	-1,861
Goodwill - ending balance	$361,325

Basis_of_Presentation_and_Sign4

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Goodwill Translation And Purchase Accounting Adjustments [Abstract]	'
Goodwill-adjustment for prior year transactions	($1,861)

Basis_of_Presentation_and_Sign5

Basis of Presentation and Significant Accounting Policies - Schedule of Total Accrued Medical Malpractice Reserves and Related Insurance Receivables (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Health Care Organizations [Abstract]	'	'
Insurance Receivable, Current Portion	$12,076	$11,653
Insurance Receivable, Long-term Portion	21,341	20,599
Insurance Receivable, Total	33,417	32,252
Claims Reserve, Current Portion	12,076	11,653
Claims Reserve, Long-term Portion	21,341	20,599
Claims Reserve, Total	33,417	32,252
IBNR Reserve, Current Portion	614	558
IBNR Reserve, Long-term Portion	24,012	23,445
IBNR Reserve, Total	24,626	24,003
Total Liabilities, Current Portion	12,690	12,211
Total Liabilities, Long-term Portion	45,353	44,044
Total Liabilities	$58,043	$56,255

Business_Acquisitions_Addition

Business Acquisitions - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014
	Hospitalist
Business Combinations [Abstract]	'
Number of hospitalist physician practices acquired	3
Period in which identifiable intangible assets amortized for tax purposes, years	'15 years

Business_Acquisitions_Schedule

Business Acquisitions - Schedule of Acquisition of Hospitalist Practices (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Acquired assets - paid and accrued:	'	'
Goodwill - 2014 transactions	$5,799	'
Other intangible assets	118	'
Total acquired assets - 2014	5,917	'
Goodwill - adjustment for prior year transactions	-1,861	'
Total acquired assets	4,056	'
Cash paid for acquisitions:	'	'
2014 transactions	-3,025	'
Contingent consideration	-5,715	'
Total cash paid for acquisitions	-8,740	-9,691
Change in fair value of contingent consideration:	'	'
Net change in fair value of contingent consideration - recognized	-383	-1,093
Net change in fair value of contingent consideration - paid	-806	'
Net change in fair value of contingent consideration	-1,189	-1,093
Net change in payable for practice acquisitions	-5,873	'
Payable for practice acquisitions, beginning of period	40,719	'
Payable for practice acquisitions, end of period	$34,846	'

Fair_Value_Measurement_Liabili

Fair Value Measurement - Liabilities Measured at Fair Value on Recurring Basis (Detail) (Fair Value, Measurements, Recurring [Member], USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified	Mar. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	$34,846
Quoted Price In Active Markets for Identical Instruments (Level 1) [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	0
Significant Other Observable Inputs (Level 2) [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	0
Significant Unobservable Inputs (Level 3) [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Accrued contingent consideration for practice acquisitions (included in payable for practice acquisitions)	$34,846

Fair_Value_Measurement_Rollfor

Fair Value Measurement - Rollforward for Liabilities Measured at Fair Value on Recurring Basis Using Significant Unobservable Inputs (Detail) (Business Combination Accrued Contingent Consideration [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Business Combination Accrued Contingent Consideration [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Beginning balance	$40,719
Addition through acquisition transactions	2,892
Adjustment for prior year transactions	-1,861
Change in fair value recognized	-383
Change in fair value paid	-806
Payments	-5,715
Ending balance	$34,846

Fair_Value_Measurement_Additio

Fair Value Measurement - Additional Information (Detail)	3 Months Ended
Fair Value Measurement - Additional Information (Detail)	Mar. 31, 2014
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'
Probability of achieving estimated projected earnings	100.00%
Minimum [Member]	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'
Discount rates on significant inputs	2.04%
Probability of acquisition of certain other hospitalist practices	25.00%
Maximum [Member]	'
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]	'
Discount rates on significant inputs	2.35%
Probability of acquisition of certain other hospitalist practices	90.00%

Debt_Additional_Information_De

Debt - Additional Information (Detail) (Revolving Credit Facility [Member], USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2014
Line of Credit Facility [Line Items]	'
Revolving line of credit borrowing capacity	$125
Additional borrowing capacity under revolving line of credit facility	25
Maturity date of Credit Facility	4-Aug-16
Amount provided by credit agreement	85
Letters of credit amount outstanding	0.3
Remaining amount available under revolving line of credit facility	$39.70
Interest rate terms	'Interest rate options for each borrowing under the Credit Facility, to be selected by us at the time of each borrowing, include either LIBOR plus 0.75% to 1.75%, or the lender's prime rate plus 0% to 0.75%, both based on a leverage ratio.
Percentage of unused commitment fee, per annum	0.25%
Revolving line of credit interest rate, per annum	1.44%
LIBOR [Member] \| Minimum [Member]	'
Line of Credit Facility [Line Items]	'
Variable interest rate, percentage in addition to base rate	0.75%
LIBOR [Member] \| Maximum [Member]	'
Line of Credit Facility [Line Items]	'
Variable interest rate, percentage in addition to base rate	1.75%
Prime Rate [Member] \| Minimum [Member]	'
Line of Credit Facility [Line Items]	'
Variable interest rate, percentage in addition to base rate	0.00%
Prime Rate [Member] \| Maximum [Member]	'
Line of Credit Facility [Line Items]	'
Variable interest rate, percentage in addition to base rate	0.75%

Income_Taxes_Schedule_of_Incom

Income Taxes - Schedule of Income Tax Provisions and Effective Tax Rates (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Abstract]	'	'
Income tax provision	$6,377	$6,521
Effective tax rate	38.30%	38.30%

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail)	3 Months Ended
Income Taxes - Additional Information (Detail)	Mar. 31, 2014
Income Tax Disclosure [Abstract]	'
Statutory U.S. federal income tax rate	35.00%
Tax examination, year under examination	'2009

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail)	Mar. 31, 2014	Jun. 07, 2012	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
			Stock Compensation Plan [Member]	Restricted Stock [Member]	Performance Stock Awards [Member]	Performance Stock Awards [Member]
					Minimum [Member]	Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'	'
Common shares reserved for issuance under stock-based employee compensation program	4,943,170	'	'	'	'	'
Common stock available for issuance under Equity Plan	894,596	1,422,130	'	'	'	'
Vesting period, in years	'	'	'4 years	'4 years	'2 years	'3 years

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized When Options, Restricted Stock Awards, Performance Stock Awards and Employee Stock Purchase Plan Shares Vested (Detail) (General and Administrative Expenses [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
General and Administrative Expenses [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total stock-based compensation expense	$1,965	$1,735
Tax benefit from stock-based compensation expense	-753	-665
Total stock-based compensation expense, net of tax	$1,212	$1,070

StockBased_Compensation_Schedu1

Stock-Based Compensation - Schedule of Unrecognized Compensation Costs Related to Non-Vested Stock-Based Compensation Arrangements Granted under Equity Plan and Weighted-Average Period of Years Expected to Recognize Those Costs (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Restricted Stock And Performance Shares [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Total Unrecognized Compensation Cost	$9,757
Weighted-average Remaining Contractual Term (Years)	'2 years 5 months 16 days
Stock Compensation Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Total Unrecognized Compensation Cost	$3,790
Weighted-average Remaining Contractual Term (Years)	'1 year 9 months 7 days

StockBased_Compensation_Schedu2

Stock-Based Compensation - Schedule of Fair Value of Each Option Grant Estimated on Date of Grant Using Black-Scholes Option-Pricing Model (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]	'	'
Risk-free interest rate	1.03%	0.66%
Expected volatility	37.05%	40.09%
Expected option life (in years)	'4 years 4 months 21 days	'4 years 5 months 1 day
Expected dividend yield	0.00%	0.00%

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of Stock Option Activities in Equity Plan (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014
Shares	'
Shares, Options outstanding as of December 31, 2013	1,380,425
Shares, Granted	39,138
Shares, Exercised	-34,129
Shares, Cancelled	-9,638
Shares, Options outstanding as of March 31, 2014	1,375,796
Shares, Options exercisable as of March 31, 2014	1,139,101
Weighted-Average Exercise Price	'
Weighted-Average Exercise Price, Options outstanding as of December 31, 2013	$30.12
Weighted-Average Exercise Price, Granted	$55.12
Weighted-Average Exercise Price, Exercised	$29.81
Weighted-Average Exercise Price, Cancelled	$43.34
Weighted-Average Exercise Price, Options outstanding as of March 31, 2014	$30.74
Weighted-Average Exercise Price, Options exercisable as of March 31, 2014	$28.24
Weighted-Average Remaining Contractual Term	'
Weighted-Average Remaining Contractual Term, Options outstanding as of March 31, 2014(Years)	'5 years 8 months 5 days
Weighted-Average Remaining Contractual Term, Options exercisable as of March 31, 2014(Years)	'5 years 4 months 6 days
Aggregate Intrinsic Value	'
Aggregate Intrinsic Value, Options outstanding as of March 31, 2014	$25,475
Aggregate Intrinsic Value, Options exercisable as of March 31, 2014	$23,781
Weighted-Average Fair Value	'
Weighted-Average Fair Value, Options outstanding as of December 31, 2013	$12.56
Weighted-Average Fair Value, Granted	$17.49
Weighted-Average Fair Value, Exercised	$12.88
Weighted-Average Fair Value, Cancelled	$18.11
Weighted-Average Fair Value, Options outstanding as of March 31, 2014	$12.66
Weighted-Average Fair Value, Options exercisable as of March 31, 2014	$11.80

StockBased_Compensation_Summar1

Stock-Based Compensation - Summary of Restricted Stock Award and Performance Stock Award Activities in Equity Plan (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014
Shares	'
Shares, Restricted/performance stock awards outstanding as of December 31, 2013	212,413
Shares, Granted	111,360
Shares, Released	-53,080
Shares, Forfeited	-5,402
Shares, Restricted/performance stock awards outstanding as of March 31, 2014	265,291
Weighted-Average Remaining Contractual Term	'
Weighted-Average Remaining Contractual Term, Restricted/performance stock awards outstanding as of March 31, 2014	'1 year 10 months 17 days
Aggregate Intrinsic Value	'
Aggregate Intrinsic Value, Restricted/performance stock awards outstanding as of March 31, 2014	$12,184
Weighted-Average Fair Value	'
Weighted-Average Fair Value, Restricted/performance stock awards outstanding as of December 31, 2013	$40.29
Weighted-Average Fair Value, Granted	$52.50
Weighted-Average Fair Value, Released	$38.69
Weighted-Average Fair Value, Forfeited	$40.97
Weighted-Average Fair Value, Restricted/performance stock awards outstanding as of March, 31 2014	$45.72

Earnings_Per_Share_Schedule_of

Earnings Per Share - Schedule of Basic and Diluted Net Income Per Share (Detail) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Basic:	'	'
Net income attributable to common stockholders	$10,274	$10,505
Weighted average number of common shares outstanding	17,054,598	16,703,369
Basic net income per share attributable to common stockholders	$0.60	$0.63
Diluted:	'	'
Net income attributable to common stockholders	$10,274	$10,505
Weighted average number of common shares outstanding	17,054,598	16,703,369
Weighted average number of dilutive common share equivalents from options to purchase common stock	512,985	422,571
Common shares and common share equivalents	17,567,583	17,125,940
Diluted net income per share	$0.58	$0.61

Earnings_Per_Share_Additional_

Earnings Per Share - Additional Information (Detail)	3 Months Ended
Earnings Per Share - Additional Information (Detail)	Mar. 31, 2014
Earnings Per Share [Abstract]	'
Total number of stock options excluded from diluted shares computation	41,254